Reperfusion injury overview

Jump to navigation Jump to search


Reperfusion injury Microchapters

Home

Overview

Pathophysiology

Risk Factors

Natural History, Complications & Prognosis

Treatment

Medical Therapy

Future or Investigational Therapies

Reperfusion injury overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Reperfusion injury overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Reperfusion injury overview

CDC on Reperfusion injury overview

Reperfusion injury overview in the news

Blogs on Reperfusion injury overview

Directions to Hospitals Treating Reperfusion injury

Risk calculators and risk factors for Reperfusion injury overview

Editors-In-Chief: Anjan K. Chakrabarti, M.D. [1]; C. Michael Gibson, M.S., M.D. [2]; Associate Editors-In-Chief: Kashish Goel, M.D.

Overview

The introduction and wide application of reperfusion strategies in patients with STEMI has significantly reduced the mortality rate over last decade. Despite this, the rate of 30-day mortality remains high and approximately 25% of surviving patients develop heart failure. One of the mechanisms responsible for these adverse outcomes is Reperfusion injury.

Pathophysiology

Reperfusion injury refers to myocardial cell death secondary to restoration of blood flow to the ischemic myocardium. The absence of oxygen and nutrients from blood creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than restoration of normal function.

Risk Factors

Risk factors for reperfusion injury include hypertension with left ventricular hypertrophy, congestive heart failure, increased age, diabetes, and hyperlipidemia.

Natural History, Complications and Prognosis

Reperfusion injury may be responsible for about 50% of the total infarct size after an acute myocardial infarction as well as myocardial stunning, congestive heart failure and reperfusion arrhythmias such as ventricular arrhythmias.[1]

Medical Therapy

While many pharmacotherapies are successful in limiting reperfusion injury in animal studies or ex-vivo, the majority have failed to improve clinical outcomes in randomized clinical trials in patients. Strategies may have failed as a result of targeting the wrong mechanism, because an inadequate dose was studied, because patients with insufficient potential for benefit were studied, and because the drug was administered too late (after reperfusion had already occurred).

References

  1. Yellon DM, Hausenloy DJ (2007). "Myocardial reperfusion injury". N. Engl. J. Med. 357 (11): 1121–35. doi:10.1056/NEJMra071667. PMID 17855673. Unknown parameter |month= ignored (help)